|
|
|
|
|
|
by raphlinus
1766 days ago
|
|
|
Several problems with this response. First, the line quoted from the highlights section is referring to the 1054 antibody, which was isolated from a patient infected with SARS-CoV-2, as opposed to one produced from vaccine response[1]. Second, the infection enhancing effect was determined in vitro. So none of that supports the idea that ADE was actually detected in a human, and particularly the idea that vaccine induced ADE has actually been observed. All that said, if the results of the paper hold up, they may help explain why the efficacy of the vaccines are reduced in the face of the delta variant. That would be extraordinarily useful in formulating better vaccines, so I'm cheering the science along. I'm less cheerful about the cherry-picking to support anti-vaccine narratives. [1]: https://www.cell.com/cell/pdf/S0092-8674(21)00756-X.pdf |
|
|
The study you cited https://www.cell.com/cell/pdf/S0092-8674(21)00756-X.pdf is specifically called out in the paper I linked, because it only looked at reactions to the Wuhan strain, which is effectively extinct.
"In a recent publication, Li et al. (Cell 184 :1-17, 2021) have reported that infection-enhancing antibodies directed against the N-terminal domain (NTD) of the SARS-CoV-2 spike protein facilitate virus infection in vitro, but not in vivo. However, this study was performed with the original Wuhan/D614G strain. Since the Covid-19 pandemic is now dominated with Delta variants, we analyzed the interaction of facilitating antibodies with the NTD of these variants."
I'm sure this post will be taken down shortly, so I wouldn't worry about it.